Results 61 to 70 of about 10,095 (153)

18FDG-PET at 1-Month Intervals Is a Better Predictive Marker for GISTs That Are Difficult to Be Diagnosed Histopathologically: A Case Report

Case Reports in Oncological Medicine, 2011
Imatinib mesylate is a tyrosine kinase inhibitor of c-KIT and PDGFRA. Imatinib mesylate is an effective drug that can be used as a first-choice agent for treatment of GISTs. Prior to treatment, molecular diagnosis of c-KIT or PDGFRA is necessary; however,
Kazunori Otsuka, Masahiro Takahashi, Hiroshi Nanjo, Hideaki Miyazawa, Masatake Iida, Yuki Abe, Mario Jin, Hirohide Onishi, Manabu Hashimoto, Yuzo Yamamoto, Hiroyuki Shibata   +10 more
doaj   +1 more source

Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)

Acta Medica, 2003
The publication provides an up-to-date review of the significance of cytogenetic abnormalities in chronic myelogenous leukemia (CML) and the development of a promising agent with specific molecular target against tyrosine kinase, product of the BCR-ABL ...
Ladislav Chrobák, Jaroslava Voglová
doaj   +1 more source

A short report on chronic myeloid leukemia from Post Graduate Institute of Medical Education and Research, Chandigarh

Indian Journal of Medical and Paediatric Oncology, 2013
Post Graduate Institute (PGI) Chandigarh is a premier institute of North India. There are approximately 70,000 admissions per year. The adult clinical hematology department sees more than 2000 new patients per year.
Pankaj Malhotra, Neelam Varma, Subhash Varma   +2 more
doaj   +1 more source

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

Haematologica, 2008
Background Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival.
Francesca Palandri, Fausto Castagnetti, Nicoletta Testoni, Simona Luatti, Giulia Marzocchi, Simona Bassi, Massimo Breccia, Giuliana Alimena, Ester Pungolino, Giovanna Rege-Cambrin, Riccardo Varaldo, Maurizio Miglino, Giorgina Specchia, Eliana Zuffa, Felicetto Ferrara, Monica Bocchia, Giuseppe Saglio, Fabrizio Pane, Daniele Alberti, Giovanni Martinelli, Michele Baccarani, Gianantonio Rosti   +21 more
doaj   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia

Haematologica, 2010
As chronic myeloid leukemia is rare in children, most data on imatinib mesylate therapy is derived from adult studies. We retrospectively evaluated pediatric (
Asim F. Belgaumi, Ali Al-Shehri, Mouhab Ayas, Mohammed Al-Mahr, Amel Al-Seraihy, Ali Al-Ahmari, Hassan El-Solh   +6 more
doaj   +1 more source

Periorbital edema secondary to imatinib mesylate

Clinical Ophthalmology, 2010
Collin M McClelland, George J Harocopos, Philip L CusterSchool of Medicine, Washington University, St. Louis, MO, USAAbstract: Imatinib mesylate (Gleevec®) is a well-established pharmacologic treatment for all phases of chronic myeloid leukemia ...
Collin M McClelland, George J Harocopos, Philip L Custer   +2 more
doaj  

Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity

International Journal of Nanomedicine, 2015
Gregory Marslin,1 Ann Mary Revina,2,3 Vinoth Kumar Megraj Khandelwal,4 Krishnamoorthy Balakumar,5 Jose Prakash,6 Gregory Franklin,1,* Caroline J Sheeba2,3,7,*1AgroBioPlant Group, Centre for the Research and Technology of Agro-Environment and Biological ...
Marslin G, Revina AM, Khandelwal VKM, Balakumar K, Prakash J, Franklin G, Sheeba CJ   +6 more
doaj  

Injectable Gamboge-Based In Situ Gel for Sustained Delivery of Imatinib Mesylate. [PDF]

Gels, 2023
Jitrangsri K, Khaing EM, Intaraphairot T, Phaechamud T, Mahadlek J.   +4 more
europepmc   +1 more source

ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment. [PDF]

Int J Mol Sci, 2023
Bochicchio MT, Marconi G, Baldazzi C, Bandini L, Ruggieri F, Lucchesi A, Agostinelli C, Sabattini E, Orsatti A, Ferrari A, Capirossi G, Servili C, Ghelli Luserna di Rorà A, Martinelli G, Simonetti G, Rosti G.   +15 more
europepmc   +1 more source